Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

N0590200

Nicotine ditartrate

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

(−)-Nicotine hydrogen tartrate salt, (−)-1-Methyl-2-(3-pyridyl)pyrrolidine (+)-bitartrate salt

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C10H14N2 · 2C4H6O6
Numero CAS:
65-31-6
Peso molecolare:
462.41
Numero CE:
200-607-2
Codice UNSPSC:
41116107
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

nicotine

Produttore/marchio commerciale

EDQM

applicazioni

pharmaceutical (small molecule)

Formato

neat

Stringa SMILE

CN1CCC[C@H]1C2=CC=CN=C2.C

InChI

1S/C10H14N2.CH4/c1-12-7-3-5-10(12)9-4-2-6-11-8-9;/h2,4,6,8,10H,3,5,7H2,1H3;1H4/t10-;/m0./s1
RYYKFQGHMYGLEL-PPHPATTJSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Nicotine ditartrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Azioni biochim/fisiol

Prototype nicotinic acetylcholine receptor agonist; naturally occurring isomer.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

Y0001023

Nicotine for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0001425

Nicotine ditartrate dihydrate, European Pharmacopoeia (EP) Reference Standard

1463304

Nicotine bitartrate dihydrate, United States Pharmacopeia (USP) Reference Standard

1327408

6-Hydroxynicotinic acid, United States Pharmacopeia (USP) Reference Standard

1463371

Nicotine Related Compound F, United States Pharmacopeia (USP) Reference Standard

1463337

Nicotine Related Compound B, United States Pharmacopeia (USP) Reference Standard

1463382

Nicotine Related Compound G, United States Pharmacopeia (USP) Reference Standard

1463326

Nicotine Related Compound A, United States Pharmacopeia (USP) Reference Standard

1463348

Nicotine Related Compound C, United States Pharmacopeia (USP) Reference Standard

1463360

Nicotine Related Compound E, United States Pharmacopeia (USP) Reference Standard

1463359

Nicotine Related Compound D, United States Pharmacopeia (USP) Reference Standard

BP822

Nicotine impurity standard, British Pharmacopoeia (BP) Reference Standard

BP821

(−)-Nicotine hydrogen tartrate salt dihydrate, British Pharmacopoeia (BP) Reference Standard

PHR2533

Nicotine Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2470

6-Hydroxynicotinic acid, Pharmaceutical Secondary Standard; Certified Reference Material

PHR3060

Nicotine Related Compound A/EP Impurity A, pharmaceutical secondary standard, certified reference material

PHR3061

Nicotine Related Compound B, pharmaceutical secondary standard, certified reference material

PHR3063

Nicotine Related Compound F, pharmaceutical secondary standard, certified reference material

PHR3064

Nicotine Related Compound G, pharmaceutical secondary standard, certified reference material

Avvertenze

Danger

Indicazioni di pericolo

H301,H319,H330,H361d,H411

Classi di pericolo

Acute Tox. 2 Inhalation - Acute Tox. 3 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - Repr. 2

Codice della classe di stoccaggio

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

289.8 °F

Punto d’infiammabilità (°C)

143.2 °C

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Ci dispiace, ma al momento non ci sono COA disponibili online per questo prodotto.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 4

1 of 4

(−)-Nicotine PESTANAL®, analytical standard

Supelco

36733

(−)-Nicotine

(±)-Nicotine ≥99% (TLC), liquid

Sigma-Aldrich

N0267

(±)-Nicotine

(−)-Nicotine solution 1.0 mg/mL, analytical standard, for drug analysis

Supelco

N5511

(−)-Nicotine solution

(-)-Nicotine for synthesis

Sigma-Aldrich

8.20877

(-)-Nicotine

Gabriel Quiroz et al.
Frontiers in pharmacology, 10, 1429-1429 (2019-12-19)
Brain nicotinic acetylcholine receptors (nAChRs), a heterogeneous family of pentameric acetylcholine-gated cation channels, have been suggested as molecular targets for the treatment of alcohol abuse and dependence. Here, we examined the effect of the competitive nAChR antagonist UFR2709 on the
José-Rubén García-Montes et al.
Molecular neurobiology, 56(6), 4037-4050 (2018-09-28)
L-DOPA is the main pharmacological therapy for Parkinson's disease. However, long-term exposure to L-DOPA induces involuntary movements termed dyskinesia. Clinical trials show that dyskinesia is attenuated by metabotropic glutamate receptor type 5 (mGluR5) antagonists. Further, the onset of dyskinesia is
Elizabeth B Rex et al.
SLAS discovery : advancing life sciences R & D, 22(2), 155-165 (2016-10-30)
Cellular signaling is in part regulated by the composition and subcellular localization of a series of protein interactions that collectively form a signaling complex. Using the α7 nicotinic acetylcholine receptor (α7nAChR) as a proof-of-concept target, we developed a platform to
Xueliang Shang et al.
Molecular neurobiology, 54(6), 4644-4658 (2016-07-14)
The aim of this study was to examine if nicotine was able to improve cognition deficits in a mouse model of chronic mild stress. Twenty-four male C57BL/6 mice were divided into three groups: control, stress, and stress with nicotine treatment.
Manal A Bakathir et al.
Saudi medical journal, 37(10), 1127-1135 (2016-09-22)
To investigate the effects of nicotine on orthodontic tooth movement and accompanying histological and immunohistochemical changes in rats. An experimental study conducted at King Abdulaziz University, Jeddah, Saudi Arabia between 2013 and 2014. Thirty-two rats randomly divided into 4 groups.
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.